New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.
You Might Also Like
Amazon’s New GLP‑1 Service Promises Less Expensive, Faster Access to Popular Weight‑Loss Drugs
Amazon ties primary care, pharmacy, and telehealth into one pipeline.
0 Min Read
MrBeast’s Company Was Just Hit With a New Lawsuit Alleging a Toxic Workplace
The lawsuit by a former executive alleges wrongful termination and paints a troubling picture of the culture inside Beast Industries.
0 Min Read
Caitlin Clark, Simone Biles and Ilia Malinin All Do 1 Thing That Every Great Leader Does Too
Being the best at what you do is only part of what makes a good leader.
0 Min Read
Ditch the Pitch. Tell a Story to Drive Conversions and Win Trust
Your clients are not buying your service. They are buying the transformation on the other side.
0 Min Read